KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Operating Leases (2019 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Operating Leases for 7 consecutive years, with $6.5 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 30.13% to $6.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.5 million through Dec 2025, down 30.13% year-over-year, with the annual reading at $6.5 million for FY2025, 30.13% down from the prior year.
  • Operating Leases hit $6.5 million in Q4 2025 for Inovio Pharmaceuticals, down from $7.3 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $19.8 million in Q1 2021 to a low of $6.5 million in Q4 2025.
  • Historically, Operating Leases has averaged $12.7 million across 5 years, with a median of $12.4 million in 2022.
  • Biggest five-year swings in Operating Leases: increased 10.92% in 2024 and later plummeted 35.24% in 2025.
  • Year by year, Operating Leases stood at $15.5 million in 2021, then fell by 18.14% to $12.7 million in 2022, then decreased by 12.83% to $11.0 million in 2023, then decreased by 15.09% to $9.4 million in 2024, then tumbled by 30.13% to $6.5 million in 2025.
  • Business Quant data shows Operating Leases for INO at $6.5 million in Q4 2025, $7.3 million in Q3 2025, and $10.7 million in Q2 2025.